米非司酮联合米索前列醇在子宫内膜不典型增生治疗中疗效评价.docVIP

米非司酮联合米索前列醇在子宫内膜不典型增生治疗中疗效评价[摘要] 目的 探讨米非司酮与米索前列醇在治疗子宫内膜不典型增生中的疗效。 方法 选取无禁忌证，拒绝手术并自愿接受米非司酮治疗的子宫内膜不典型增生患者40例，随机分为治疗组和对照组，每组20例，分别采用米非司酮联合米索前列醇治疗方案和传统的甲羟孕酮单一用药方案进行治疗。 结果 米非司酮联合米索前列醇治疗组的疗效明显优于甲羟孕酮单一用药组，差异具有统计学意义（P ＜ 0.05）。 结论 采用米非司酮联合米索前列醇治疗方案治疗子宫内膜不典型增生安全有效。 [关键词] 子宫内膜不典型增生；米非司酮；米索前列醇；甲羟孕酮 [中图分类号] R711.7 [文献标识码] A [文章编号] 1674-4721（2012）06（a）-0086-02 The efficacy evaluation of mifepristone and misoprostol in treatment of atypical endometrial hyperplasia XU Fenghua1 ZHANG Lihua2 1.Department of Gynecology and Obstetrics, Lingyuan Gangcheng Central Hospital in Liaoning Province, Lingyuan 122500, China; 2.Department of Pathology of Chao yang Health School, Liaoning Province, Chaoyang 122000, China [Abstract] Objective To discuss the effect of mifepristone and misoprostol in treatment of endometrial dysplasia. Methods Forty cases of endometrial atypical hyperplasia patients who had no contraindication, refused to surgery and accept the treatment were randomly divided into treatment group and control group, 20 cases in each. The treatment group were given mifepristone joint with misoprostol and control group were given traditional medroxyprogesterone acetate single treatment. Results The treatment group had better effects than that of control group, there was statistically significant difference between the two groups (P ＜ 0.05). Conclusion The treatment of mifepristone combined misoprostol in endometrial dysplasia is safe and effective. [Key words] Endometrial dysplasia; Mifepristone; Misoprostol; Medroxyprogesterone acetate 子宫内膜不典型增生是子宫内膜增殖症的的一种，也称子宫内膜增生过长主要表现是不规则阴道出血和月经量过多，多见于青春期或绝经期妇女，主要与卵巢功能紊乱导致雌激素分泌过多而孕激素缺乏有关[1]。约有1/3的患者可发展成子宫内膜癌。因此患者有发生贫血及癌变的风险。根据激素对子宫内膜的影响以及子宫内膜不典型增生的原因，传统上非手术治疗主要采用孕激素进行药物治疗。但采用孕激素治疗有一定的致癌风险，而且复发的概率较大。近年来，本院采用米非司酮联合米索前列醇方案治疗子宫内膜不典型增生，并把疗效与单纯使用甲羟孕酮单一用药组进行对比，现报道如下： 1 资料与方法 1.1 一般资料 对2008年9月～2011年9月在本院门诊就诊的子宫内膜不典型增生的患者的临床资料进行回顾性分析，随机选取采用米非司酮与米索前列醇联合用药做为治疗方案病例资料20例作为治疗组，选取20例采用甲羟孕酮治疗的子宫内膜不典型增生患者资料20例做为对照组；患者平均年龄为（42.1±4.1）岁，两组患者一般资料